Skip to main content

Drug Interactions between Berkley and Jensen Acid Reducer Maximum Strength and didanosine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

raNITIdine didanosine

Applies to: Berkley and Jensen Acid Reducer Maximum Strength (ranitidine) and didanosine

Ranitidine may slightly increase the bioavailability of didanosine by increasing gastric pH. This interaction is unlikely to be clinically significant.

References (2)
  1. Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH (1992) "Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus." Antimicrob Agents Chemother, 36, p. 2075-9
  2. (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb

Drug and food interactions

Moderate

didanosine food

Applies to: didanosine

ADJUST DOSING INTERVAL: Didanosine bioavailability is decreased when administered with food. Loss of efficacy may result.

MANAGEMENT: Didanosine should be administered in the fasting state, at least 30 minutes before or more than 2 hours after eating.

References (1)
  1. (2002) "Product Information. Videx (didanosine)." Bristol-Myers Squibb
Minor

raNITIdine food

Applies to: Berkley and Jensen Acid Reducer Maximum Strength (ranitidine)

H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.

References (1)
  1. Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer